Relypsa Company Profile (NASDAQ:RLYP)

About Relypsa

Relypsa logoRelypsa, Inc. is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company's technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address. Its polymers are non-absorbed, meaning they act within the gastrointestinal tract and do not get absorbed into the bloodstream or other parts of the body. Its polymer technology may be able to address many health conditions in need of viable treatment options. Its VELTASSA (patiromer) for oral suspension is a commercialized medicine resulting from its polymer technology platform. VELTASSA is a potassium binder approved for the treatment of hyperkalemia. Available in powder form, VELTASSA is mixed with water and taken daily. VELTASSA's spherical beads bind to potassium in exchange for calcium, primarily in the colon.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RLYP
  • CUSIP:
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $30.31
  • 200 Day Moving Average: $20.28
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.13
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Beta: 2.19
Additional Links:
Companies Related to Relypsa:

Analyst Ratings

Consensus Ratings for Relypsa (NASDAQ:RLYP) (?)
Ratings Breakdown: 10 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.23)
Consensus Price Target: $31.82 (0.54% downside)

Analysts' Ratings History for Relypsa (NASDAQ:RLYP)
DateFirmActionRatingPrice TargetDetails
9/1/2016BTIG ResearchDowngradeBuy -> NeutralView Rating Details
9/1/2016WedbushDowngradeOutperform -> Neutral$32.00View Rating Details
8/22/2016Stifel NicolausDowngradeBuy -> Hold$32.00View Rating Details
8/13/2016MizuhoReiterated RatingNeutral$32.00View Rating Details
8/8/2016Cantor FitzgeraldReiterated RatingHold$32.00View Rating Details
7/22/2016HC WainwrightDowngradeBuy -> Neutral$32.00View Rating Details
7/21/2016Morgan StanleyUpgradeUnderweight -> Equal Weight$9.00 -> $32.00View Rating Details
7/21/2016Citigroup Inc.DowngradeBuy -> Neutral$25.00 -> $32.00View Rating Details
7/21/2016Brean CapitalDowngradeBuy -> HoldView Rating Details
5/31/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperform$36.00View Rating Details
5/29/2016Cowen and CompanyReiterated RatingBuyView Rating Details
4/1/2016Raymond James Financial, Inc.Initiated CoverageMarket PerformView Rating Details
2/25/2016Bank of America CorpReiterated RatingBuy$32.00 -> $29.00View Rating Details
11/4/2015GuggenheimInitiated CoverageBuy$46.00View Rating Details
10/27/2015NomuraReiterated RatingOutperform$75.00View Rating Details
(Data available from 2/20/2015 forward)


Earnings History for Relypsa (NASDAQ:RLYP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2016Q1($1.46)($1.26)$6.88 million$12.40 millionViewListenView Earnings Details
2/24/2016Q415($1.35)($1.40)$7.37 million$11.96 millionViewListenView Earnings Details
11/4/2015Q3($0.89)($1.24)$6.67 million$6.50 millionViewN/AView Earnings Details
8/6/2015($0.95)($0.95)$0.01 millionViewN/AView Earnings Details
5/7/2015($0.87)($0.78)ViewN/AView Earnings Details
3/11/2015Q414($0.68)($0.80)ViewN/AView Earnings Details
11/10/2014($0.61)($0.57)ViewN/AView Earnings Details
8/11/2014($0.57)($0.51)ViewN/AView Earnings Details
5/7/2014($0.56)($0.54)ViewN/AView Earnings Details
3/17/2014Q413($0.50)($0.68)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Relypsa (NASDAQ:RLYP)
Current Year EPS Consensus Estimate: $-6.33 EPS
Next Year EPS Consensus Estimate: $-6.24 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.61)($1.42)($1.52)
Q2 20162($1.53)($1.43)($1.48)
Q3 20162($1.65)($1.47)($1.56)
Q4 20162($1.65)($1.40)($1.53)
Q1 20171($1.65)($1.65)($1.65)
Q2 20171($1.64)($1.64)($1.64)
Q3 20171($1.62)($1.62)($1.62)
Q4 20171($1.59)($1.59)($1.59)
(Data provided by Zacks Investment Research)


Dividend History for Relypsa (NASDAQ:RLYP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Relypsa (NASDAQ:RLYP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/17/2016James D DonderoMajor ShareholderBuy500$31.92$15,960.00View SEC Filing  
8/16/2016Monte MontgomeryInsiderSell510$31.92$16,279.20View SEC Filing  
8/11/2016James D DonderoMajor ShareholderSell37,000$31.96$1,182,520.00View SEC Filing  
7/25/2016Orbimed Advisors LlcMajor ShareholderSell4,043,600$32.00$129,395,200.00View SEC Filing  
6/7/2016David W J McgirrDirectorSell1,013$19.34$19,591.42View SEC Filing  
3/16/2016Kristine M BallCFOBuy7,000$12.15$85,050.00View SEC Filing  
3/15/2016Thomas J SchuetzDirectorBuy30,000$13.39$401,700.00View SEC Filing  
12/31/2015Wilhelm StahlSVPSell20,000$28.53$570,600.00View SEC Filing  
12/23/2015Orbimed Advisors LlcMajor ShareholderSell500,000$27.18$13,590,000.00View SEC Filing  
12/9/2015Lance BermanSVPSell750$29.50$22,125.00View SEC Filing  
12/7/2015John A. OrwinCEOSell15,000$28.28$424,200.00View SEC Filing  
12/7/2015Lance BermanSVPSell30,000$29.78$893,400.00View SEC Filing  
12/4/2015John A. OrwinCEOSell40,000$25.00$1,000,000.00View SEC Filing  
10/22/2015Orbimed Advisors LlcMajor ShareholderBuy500,000$12.56$6,280,000.00View SEC Filing  
8/17/2015John A OrwinCEOSell5,000$24.84$124,200.00View SEC Filing  
8/17/2015Lance BermanSVPSell710$24.77$17,586.70View SEC Filing  
8/17/2015Ronald A KrasnowInsiderSell522$24.75$12,919.50View SEC Filing  
6/11/2015Thomas J SchuetzDirectorSell1,000$34.57$34,570.00View SEC Filing  
6/1/2015John A OrwinCEOSell33,555$36.42$1,222,073.10View SEC Filing  
5/18/2015Orbimed Advisors LlcMajor ShareholderSell1,457,551$34.13$49,746,215.63View SEC Filing  
5/11/2015Klaus R Dr VeitingerDirectorSell5,834$36.06$210,374.04View SEC Filing  
4/10/2015Klaus R Dr VeitingerDirectorSell5,832$35.35$206,161.20View SEC Filing  
3/5/2015Kristine M BallCFOSell3,519$40.68$143,152.92View SEC Filing  
2/27/2015Ronald A KrasnowInsiderSell10,348$39.00$403,572.00View SEC Filing  
2/24/2015Lance BermanSVPSell5,000$38.19$190,950.00View SEC Filing  
2/24/2015Ronald A KrasnowInsiderSell10,000$39.00$390,000.00View SEC Filing  
2/10/2015Klaus R Dr VeitingerDirectorSell5,834$32.12$187,388.08View SEC Filing  
1/21/2015Claire LockeyInsiderSell5,000$35.00$175,000.00View SEC Filing  
1/21/2015Kristine M BallCFOSell3,000$36.00$108,000.00View SEC Filing  
1/14/2015Ronald A KrasnowInsiderSell5,000$33.58$167,900.00View SEC Filing  
1/12/2015Klaus R Dr VeitingerDirectorSell5,834$32.33$188,613.22View SEC Filing  
12/12/2014Klaus R Dr VeitingerDirectorSell14,169$32.16$455,675.04View SEC Filing  
12/9/20145Am Partners Iii, LlcMajor ShareholderSell589,637$30.04$17,712,695.48View SEC Filing  
12/9/2014Claire LockeyInsiderSell8,000$30.00$240,000.00View SEC Filing  
11/25/2014Lance BermanSVPSell30,000$25.00$750,000.00View SEC Filing  
10/10/2014Klaus R Dr VeitingerDirectorSell2,500$19.34$48,350.00View SEC Filing  
9/24/2014Lance BermanSVPSell5,000$22.00$110,000.00View SEC Filing  
9/17/2014Orbimed Advisors LlcMajor ShareholderSell94,000$25.27$2,375,380.00View SEC Filing  
9/16/20145Am Partners Ii, LlcMajor ShareholderSell612,540$26.03$15,944,416.20View SEC Filing  
9/10/2014Klaus R Dr VeitingerDirectorSell4,167$23.00$95,841.00View SEC Filing  
8/29/2014Wilhelm StahlSVPSell15,785$25.29$399,202.65View SEC Filing  
8/26/20145Am Partners Ii, LlcMajor ShareholderSell433,000$26.51$11,478,830.00View SEC Filing  
8/25/2014Lance BermanSVPSell20,000$25.89$517,800.00View SEC Filing  
8/11/2014Klaus R Dr VeitingerDirectorSell4,167$27.73$115,550.91View SEC Filing  
7/24/2014Lance BermanSVPSell45,000$23.92$1,076,400.00View SEC Filing  
7/10/2014Klaus R Dr VeitingerDirectorSell4,167$23.12$96,341.04View SEC Filing  
11/20/20135Am Partners Iii, LlcMajor ShareholderBuy372,692$11.00$4,099,612.00View SEC Filing  
11/20/2013John A OrwinCEOBuy15,000$11.00$165,000.00View SEC Filing  
11/20/2013Leaf Ventures I L.P. NewInsiderBuy185,978$11.00$2,045,758.00View SEC Filing  
11/20/2013Scott M RocklageDirectorBuy363,328$11.00$3,996,608.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Relypsa (NASDAQ:RLYP)
DateHeadline logo3 Beaten Biotech Stocks That Are Set to Rebound - Nasdaq (NASDAQ:RLYP) - February 7 at 8:23 AM
News IconShould You Buy Or Sell Relypsa, Inc. (NASDAQ:RLYP) On Analyst Concensus? - NewsDen (NASDAQ:RLYP) - February 4 at 7:38 PM
News IconEarnings in Full Force, Analysts Take Aim at Relypsa, Inc. (NASDAQ:RLYP) - Wall Street Beacon (NASDAQ:RLYP) - January 28 at 7:42 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Relypsa, Inc. (NASDAQ:RLYP) - Wall Street Beacon (NASDAQ:RLYP) - January 20 at 6:31 AM
News IconWill The Needle Move For Relypsa, Inc. (NASDAQ:RLYP) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:RLYP) - January 13 at 1:14 AM logoThe 7 Biggest Market Rumors Of 2016: Where Are They Now? - Benzinga (NASDAQ:RLYP) - December 22 at 2:32 AM logoRelypsa Announces Data on the Treatment and Impact of Hyperkalemia to be Presented at ASN Kidney Week 2016 (NASDAQ:RLYP) - November 3 at 7:10 PM
News IconLatest Analyst Reports On Relypsa, Inc. - NewsDen (NASDAQ:RLYP) - October 20 at 8:33 AM
News IconRelypsa, Inc. (NASDAQ:RLYP) Updated Analyst Coverage - NewsDen (NASDAQ:RLYP) - October 10 at 6:35 PM logoRelypsa Inc (RLYP) Downgraded To A Neutral At Wedbush; Here's Why (NASDAQ:RLYP) - September 4 at 11:06 AM logoRelypsa Inc (RLYP) Downgraded To A Neutral At Wedbush; Here's Why - TCC (NASDAQ:RLYP) - September 2 at 6:57 PM logoGalenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies (NASDAQ:RLYP) - September 2 at 11:59 AM logoSome clouds might have a silver lining, according to Wedbush (NASDAQ:RLYP) - September 1 at 7:01 PM logoGalenica Announces 85.6% of Relypsa (RLYP) Shares Have Been Tendered (NASDAQ:RLYP) - September 1 at 7:01 PM logoGalenica announces Expiration of Cash Tender Offer for Shares of Common Stock of Relypsa (NASDAQ:RLYP) - September 1 at 10:13 AM logoRELYPSA INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Triggering Events That Accelerate or (NASDAQ:RLYP) - September 1 at 10:13 AM logoRelypsa downgraded by Stifel (NASDAQ:RLYP) - August 30 at 7:00 PM logo4:05 pm Relypsa announces that the Phase 4 TOURMALINE study, which evaluated the efficacy and safety of Veltassa for oral suspension with or without food for the treatment of hyperkalemia, met its primary endpoint (NASDAQ:RLYP) - August 30 at 7:00 PM logoRelypsa Announces Phase 4 Study Shows Veltassa® Demonstrated Similar Efficacy and Safety Whether Given With or Without Food in Patients with Hyperkalemia (NASDAQ:RLYP) - August 30 at 7:00 PM
News IconHC Stocks Growth: Zoetis Inc (ZTS), Relypsa Inc (NASDAQ:RLYP) - share market updates (press release) (NASDAQ:RLYP) - August 30 at 10:23 AM
News IconInvestor News: Lawsuit against Buyout of Relypsa Inc (NASDAQ:RLYP) filed (NASDAQ:RLYP) - August 29 at 11:42 AM
News IconOverbuying Stock in Spotlight: Relypsa Inc (NASDAQ:RLYP) - Post Registrar (NASDAQ:RLYP) - August 24 at 6:52 PM logoLawsuit for Investors in Relypsa Inc (NASDAQ:RLYP) in Effort to Halt the Takeover by Galenica Group (NASDAQ:RLYP) - August 22 at 7:03 PM
News IconHC Stocks Outlines: Relypsa Inc (NASDAQ:RLYP), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - share market updates (press release) (NASDAQ:RLYP) - August 18 at 10:09 AM
News IconInsider Trading in Focus: Relypsa Inc (NASDAQ:RLYP) - Post Registrar (NASDAQ:RLYP) - August 17 at 7:29 PM logoGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Relypsa, Inc. (RLYP) (NASDAQ:RLYP) - August 15 at 7:32 PM logoRELYPSA INC Financials (NASDAQ:RLYP) - August 12 at 7:15 PM
News IconAnalyst's Estimates on Shares' Price: Relypsa Inc (NASDAQ:RLYP) - Post Registrar (NASDAQ:RLYP) - August 9 at 7:27 PM logoNew details reveal Relypsa is a hot commodity (NASDAQ:RLYP) - August 9 at 7:27 PM logoHighland Capital Management Reveals Investment In Relypsa (RLYP) (NASDAQ:RLYP) - August 9 at 10:23 AM
News IconHC Stocks Newsbeat: Relypsa Inc (NASDAQ:RLYP), CVS Health Corp (NYSE:CVS) - share market updates (press release) (NASDAQ:RLYP) - August 8 at 11:55 AM logoProcess To Acquire Relypsa Inc (NASDAQ:RLYP) Kicks Off (NASDAQ:RLYP) - August 6 at 7:10 PM logoCantor Reiterates Hold on Relypsa Inc (RLYP) Following 2Q:16 Results - Smarter Analyst (NASDAQ:RLYP) - August 5 at 7:22 PM


What is Relypsa's stock symbol?

Relypsa trades on the NASDAQ under the ticker symbol "RLYP."

Where is Relypsa's stock going? Where will Relypsa's stock price be in 2017?

13 analysts have issued 12 month price targets for Relypsa's shares. Their forecasts range from $26.00 to $36.00. On average, they anticipate Relypsa's share price to reach $31.82 in the next year.

When will Relypsa announce their earnings?

Relypsa is scheduled to release their next quarterly earnings announcement on Friday, August, 5th 2016.

What are analysts saying about Relypsa stock?

Here are some recent quotes from research analysts about Relypsa stock:

  • Oppenheimer Holdings, Inc. analysts commented, "FDA issued a complete response letter for ZS-9, citing issues observed during a pre- approval manufacturing inspection and receipt of recently-submitted data, which it has yet to review. While there is still the chance that ZS-9 is approved and that this is only a delay (albeit a significant one), no guidance was given on the timing of when the manufacturing issues could be resolved. Our expectation was that ZS-9 would get approved and that there would be some language/black-box warning in the label surrounding the edema rates previously observed." (5/31/2016)

  • Brean Capital analysts commented, "Relypsa disclosed April prescription data in the 8-K yesterday. The numbers, including retail and non-retail TRx, were solid, though not impressive. As we have reiterated in the past, uptake of Veltassa will continue to be slow in the near term. However, the data was not bad enough to warrant a change in our investment thesis given that demand varies m/m and 1 additional data point does not demonstrate the underlying trend of Veltassa uptake going forward." (5/17/2016)

  • According to Zacks Investment Research, "Relypsa, Inc. is a pharmaceutical company focused on the development and commercialization of nonabsorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. Relypsa, Inc. is headquartered in Redwood City, California. " (5/10/2016)

  • BTIG Research analysts commented, "Unlikely" (5/5/2016)

How do I buy Relypsa stock?

Shares of Relypsa can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Relypsa stock cost?

One share of Relypsa stock can currently be purchased for approximately $31.99.

Relypsa (NASDAQ:RLYP) Chart for Monday, February, 20, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Relypsa (NASDAQ:RLYP)

Earnings History Chart

Earnings by Quarter for Relypsa (NASDAQ:RLYP)

Dividend History Chart

Dividend Payments by Quarter for Relypsa (NASDAQ:RLYP)

Last Updated on 2/20/2017 by Staff